Skip to content

H.R. 8205 · 119th Congress (2025–2027)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This act reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The act reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.

Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs.

Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Show official title

To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

Enacted

Public law number: P.L. 119-138

This bill’s path

211 days after it was introduced

This is H.R. 8205’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced4 months

  2. Passed House

  3. Passed Senate

  4. Resolving differences

    Not neededsame bill text

  5. Sent to President

  6. Signed into law

Sponsor
Rep. Mike Quigley (D-IL-5)
Cosponsors
103 cosponsors

1 original · 102 later

39 R · 64 D

  1. Rep. Ken Calvert (R-CA-41)· Original · Apr 6, 2026
  2. Rep. Jake Auchincloss (D-MA-4)· Later · Apr 9, 2026
  3. Rep. Angie Craig (D-MN-2)· Later · Apr 9, 2026
  4. Rep. Scott DesJarlais (R-TN-4)· Later · Apr 9, 2026
  5. Rep. Brian K. Fitzpatrick (R-PA-1)· Later · Apr 9, 2026
  6. Rep. Michael T. McCaul (R-TX-10)· Later · Apr 9, 2026
  7. Rep. Janice D. Schakowsky (D-IL-9)· Later · Apr 9, 2026
  8. Rep. Jason Crow (D-CO-6)· Later · Apr 14, 2026
  9. Rep. Jeff Hurd (R-CO-3)· Later · Apr 14, 2026
  10. Rep. Gwen Moore (D-WI-4)· Later · Apr 14, 2026
  11. Rep. Bradley Scott Schneider (D-IL-10)· Later · Apr 14, 2026
  12. Rep. Glenn Thompson (R-PA-15)· Later · Apr 14, 2026
  13. Rep. David G. Valadao (R-CA-22)· Later · Apr 14, 2026
  14. Rep. Suzanne Bonamici (D-OR-1)· Later · Apr 15, 2026
  15. Rep. David P. Joyce (R-OH-14)· Later · Apr 15, 2026
  16. Rep. Maria Elvira Salazar (R-FL-27)· Later · Apr 15, 2026
  17. Rep. Marc A. Veasey (D-TX-33)· Later · Apr 15, 2026
  18. Rep. Gus M. Bilirakis (R-FL-12)· Later · Apr 16, 2026
  19. Rep. Andrew R. Garbarino (R-NY-2)· Later · Apr 16, 2026
  20. Rep. Stephen F. Lynch (D-MA-8)· Later · Apr 16, 2026
  21. Rep. Brad Sherman (D-CA-32)· Later · Apr 16, 2026
  22. Rep. Don Bacon (R-NE-2)· Later · Apr 20, 2026
  23. Rep. Tom Cole (R-OK-4)· Later · Apr 20, 2026
  24. Rep. Steve Cohen (D-TN-9)· Later · Apr 20, 2026
  25. Rep. Madeleine Dean (D-PA-4)· Later · Apr 20, 2026
  26. Rep. Valerie P. Foushee (D-NC-4)· Later · Apr 20, 2026
  27. Rep. Jay Obernolte (R-CA-23)· Later · Apr 20, 2026
  28. Rep. Pete Sessions (R-TX-17)· Later · Apr 20, 2026
  29. Rep. Adam Smith (D-WA-9)· Later · Apr 20, 2026
  30. Rep. John H. Rutherford (R-FL-5)· Later · Apr 21, 2026
  31. Rep. Terri A. Sewell (D-AL-7)· Later · Apr 21, 2026
  32. Rep. Danny K. Davis (D-IL-7)· Later · Apr 22, 2026
  33. Rep. Joe Wilson (R-SC-2)· Later · Apr 22, 2026
  34. Rep. Robert B. Aderholt (R-AL-4)· Later · Apr 23, 2026
  35. Rep. Ritchie Torres (D-NY-15)· Later · Apr 23, 2026
  36. Rep. Tracey Mann (R-KS-1)· Later · Apr 30, 2026
  37. Del. Eleanor Holmes Norton (D-DC)· Later · Apr 30, 2026
  38. Rep. Raja Krishnamoorthi (D-IL-8)· Later · May 4, 2026
  39. Rep. Jefferson Van Drew (R-NJ-2)· Later · May 4, 2026
  40. Rep. Mark Alford (R-MO-4)· Later · May 7, 2026
  41. Rep. Nick LaLota (R-NY-1)· Later · May 7, 2026
  42. Rep. Kim Schrier (D-WA-8)· Later · May 7, 2026
  43. Rep. Lauren Underwood (D-IL-14)· Later · May 7, 2026
  44. Rep. Debbie Dingell (D-MI-6)· Later · May 11, 2026
  45. Rep. Chuck Edwards (R-NC-11)· Later · May 11, 2026
  46. Rep. Young Kim (R-CA-40)· Later · May 11, 2026
  47. Rep. Doris O. Matsui (D-CA-7)· Later · May 11, 2026
  48. Rep. Mike Bost (R-IL-12)· Later · May 12, 2026
  49. Rep. Mike Thompson (D-CA-4)· Later · May 12, 2026
  50. Rep. Paul Tonko (D-NY-20)· Later · May 12, 2026
  51. Rep. Rashida Tlaib (D-MI-12)· Later · May 12, 2026
  52. Rep. Tim Walberg (R-MI-5)· Later · May 12, 2026
  53. Rep. Randy K. Weber, Sr. (R-TX-14)· Later · May 12, 2026
  54. Rep. Stephanie I. Bice (R-OK-5)· Later · May 13, 2026
  55. Rep. Suzan K. DelBene (D-WA-1)· Later · May 13, 2026
  56. Rep. J. Luis Correa (D-CA-46)· Later · May 14, 2026
  57. Rep. Mario Diaz-Balart (R-FL-26)· Later · May 14, 2026
  58. Rep. Timothy M. Kennedy (D-NY-26)· Later · May 14, 2026
  59. Rep. Darin LaHood (R-IL-16)· Later · May 14, 2026
  60. Rep. Steve Womack (R-AR-3)· Later · May 15, 2026
  61. Rep. George Whitesides (D-CA-27)· Later · May 15, 2026
  62. Rep. Sanford D. Bishop, Jr. (D-GA-2)· Later · May 19, 2026
  63. Rep. David Rouzer (R-NC-7)· Later · May 19, 2026
  64. Rep. Robin L. Kelly (D-IL-2)· Later · May 21, 2026
  65. Rep. Julia Letlow (R-LA-5)· Later · May 21, 2026
  66. Rep. Mark E. Amodei (R-NV-2)· Later · May 26, 2026
  67. Rep. Josh Gottheimer (D-NJ-5)· Later · May 26, 2026
  68. Rep. Tim Moore (R-NC-14)· Later · May 29, 2026
  69. Rep. John R. Carter (R-TX-31)· Later · Jun 2, 2026
  70. Rep. Emanuel Cleaver (D-MO-5)· Later · Jun 2, 2026
  71. Rep. Greg Stanton (D-AZ-4)· Later · Jun 2, 2026
  72. Rep. Eugene Simon Vindman (D-VA-7)· Later · Jun 10, 2026
  73. Rep. Robert J. Wittman (R-VA-1)· Later · Jun 10, 2026
  74. Rep. Janelle S. Bynum (D-OR-5)· Later · Jun 11, 2026
  75. Rep. Michael Guest (R-MS-3)· Later · Jun 11, 2026
  76. Rep. Alma S. Adams (D-NC-12)· Later · Jul 9, 2026
  77. Rep. Joyce Beatty (D-OH-3)· Later · Jul 9, 2026
  78. Rep. Nikki Budzinski (D-IL-13)· Later · Jul 9, 2026
  79. Rep. Sean Casten (D-IL-6)· Later · Jul 9, 2026
  80. Rep. Troy A. Carter (D-LA-2)· Later · Jul 9, 2026
  81. Rep. Herbert C. Conaway, Jr. (D-NJ-3)· Later · Jul 9, 2026
  82. Rep. Donald G. Davis (D-NC-1)· Later · Jul 9, 2026
  83. Rep. Adelita S. Grijalva (D-AZ-7)· Later · Jul 9, 2026
  84. Rep. James A. Himes (D-CT-4)· Later · Jul 9, 2026
  85. Rep. Jahana Hayes (D-CT-5)· Later · Jul 9, 2026
  86. Rep. Jonathan L. Jackson (D-IL-1)· Later · Jul 9, 2026
  87. Rep. Marcy Kaptur (D-OH-9)· Later · Jul 9, 2026
  88. Rep. John B. Larson (D-CT-1)· Later · Jul 9, 2026
  89. Rep. Greg Landsman (D-OH-1)· Later · Jul 9, 2026
  90. Rep. George Latimer (D-NY-16)· Later · Jul 9, 2026
  91. Rep. Carol D. Miller (R-WV-1)· Later · Jul 9, 2026
  92. Rep. Seth Magaziner (D-RI-2)· Later · Jul 9, 2026
  93. Rep. Sarah McBride (D-DE)· Later · Jul 9, 2026
  94. Rep. Analilia Mejia (D-NJ-11)· Later · Jul 9, 2026
  95. Rep. Chellie Pingree (D-ME-1)· Later · Jul 9, 2026
  96. Rep. Scott H. Peters (D-CA-50)· Later · Jul 9, 2026
  97. Rep. Deborah K. Ross (D-NC-2)· Later · Jul 9, 2026
  98. Rep. Josh Riley (D-NY-19)· Later · Jul 9, 2026
  99. Rep. Thomas R. Suozzi (D-NY-3)· Later · Jul 9, 2026
  100. Rep. Mary Gay Scanlon (D-PA-5)· Later · Jul 9, 2026
  101. Rep. Melanie A. Stansbury (D-NM-1)· Later · Jul 9, 2026
  102. Rep. Eric Sorensen (D-IL-17)· Later · Jul 9, 2026
  103. Rep. Bonnie Watson Coleman (D-NJ-12)· Later · Jul 9, 2026
Policy area
Health
Subjects
  • Department of Health and Human Services
  • Drug therapy
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Health programs administration and funding
  • Internet, web applications, social media
  • Medical research
  • National Institutes of Health (NIH)
  • 3 more
    • Neurological disorders
    • Public-private cooperation
    • Research administration and funding

On this page

Spending

The enacted law text (Public Law 119–138) is not available locally.

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

Jump to latest
  1. Referred to Health

    Referred to the Subcommittee on Health.

    Sources
  2. Introduced in House

    Document: Introduced in House

    Sources
  3. ▸ 6 committee actions · Apr 6, 2026 – Jul 9, 2026
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Subcommittee markup session held

      Subcommittee Consideration and Mark-up Session Held

      Sources
    3. Forwarded by subcommittee

      Forwarded by Subcommittee to Full Committee by Voice Vote.

      Sources
    4. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    5. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

      Sources
    6. Reported by committee

      Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

      Sources
  4. Passed House

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    The House passed the bill as amended.

    Document: Engrossed in House

    Sources
  5. Passed Senate

    Congressional Record S5120

    Passed Senate without amendment by Voice Vote.

    The Senate passed the bill.

    Sources
  6. Enrolled Bill

    Congress published an enrolled text of the bill.

    Document: Enrolled Bill

    Sources
  7. Presented to the President

    Presented to President.

    Sources
  8. Latest

    Law

    Signed by President

    Became Public Law 119–138.

    Document: Public Law

    Sources

Committees

  1. HouseEnergy and CommerceReferred Apr 6, 2026 · Markup May 21, 2026 · Reported Jul 9, 2026H. Rept. 119-733
    1. H. Rept. 119-733 · Jul 9, 2026 · Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026
  2. HouseHealthReferred Apr 6, 2026 · Markup May 13, 2026 · Reported May 13, 2026
    1. May 13, 2026 · Markup

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Jul 20, 2026 · House · Considered under suspension of the rulesCongressional Record H4652–H4654

    Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026

  2. Jul 22, 2026 · House · Considered as unfinished businessCongressional Record H5159

    Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026

  3. Sep 28, 2026 · Senate · Passed Senate without amendment by Voice VoteCongressional Record S5120

    Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Engrossed in House
Placed on Calendar Senate
Public Law
Enrolled Bill—
Titles (2)
  1. Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

    Display title, Short title · Enrolled Bill, Placed on Calendar Senate, Engrossed in House, Reported in House, Introduced in House

  2. To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

    Official title · Engrossed in House, Introduced in House